$735 Million is the total value of Eventide Asset Management's 104 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 37.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $22,475,000 | +26.4% | 490,500 | +8.0% | 3.06% | +10.7% |
| MDVN | Buy | MEDIVATION INC | $21,220,000 | +24.6% | 275,300 | +4.1% | 2.89% | +9.2% |
| EOG | Buy | EOG RES INC | $16,921,000 | +19.1% | 144,800 | +100.0% | 2.30% | +4.4% |
| ABBV | Buy | ABBVIE INC | $16,520,000 | +11.7% | 292,700 | +1.7% | 2.25% | -2.1% |
| CELG | New | CELGENE CORP | $16,317,000 | – | 190,000 | +100.0% | 2.22% | – |
| WBC | Buy | WABCO HLDGS INC | $15,713,000 | +15.9% | 147,100 | +14.6% | 2.14% | +1.6% |
| RHT | Buy | RED HAT INC | $14,790,000 | +20.2% | 267,600 | +15.2% | 2.01% | +5.2% |
| LLTC | Buy | LINEAR TECHNOLOGY CORP | $13,773,000 | +3.5% | 292,600 | +7.1% | 1.87% | -9.3% |
| SYNA | New | SYNAPTICS INC | $13,333,000 | – | 147,100 | +100.0% | 1.81% | – |
| DYAX | Buy | DYAX CORP | $12,772,000 | +11.3% | 1,330,400 | +4.1% | 1.74% | -2.5% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $12,029,000 | +19.2% | 773,600 | +50.7% | 1.64% | +4.5% |
| WAB | Buy | WABTEC CORP | $11,951,000 | +13.6% | 144,700 | +6.6% | 1.62% | -0.5% |
| STKL | Buy | SUNOPTA INC | $11,751,000 | +21.0% | 834,600 | +1.5% | 1.60% | +6.0% |
| CPN | Buy | CALPINE CORP | $11,360,000 | +28.1% | 477,100 | +12.5% | 1.54% | +12.2% |
| UFS | Buy | DOMTAR CORP | $11,081,000 | -23.6% | 258,600 | +100.0% | 1.51% | -33.1% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $10,867,000 | +15.4% | 372,400 | +2.4% | 1.48% | +1.1% |
| DATA | New | TABLEAU SOFTWARE INCcl a | $10,707,000 | – | 150,100 | +100.0% | 1.46% | – |
| ININ | Buy | INTERACTIVE INTELLIGENCE GRO | $10,339,000 | -16.6% | 184,200 | +7.8% | 1.41% | -26.9% |
| CXP | Buy | COLUMBIA PPTY TR INC | $10,243,000 | +11.9% | 393,800 | +17.3% | 1.39% | -2.0% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $9,560,000 | +103.1% | 423,200 | +118.7% | 1.30% | +77.8% |
| VMW | Buy | VMWARE INC | $9,468,000 | +11.5% | 97,800 | +24.4% | 1.29% | -2.3% |
| NRG | Buy | NRG ENERGY INC | $9,426,000 | +53.3% | 253,400 | +31.0% | 1.28% | +34.2% |
| LGND | Buy | LIGAND PHARMACEUTICALS INC | $9,325,000 | -6.3% | 149,700 | +1.2% | 1.27% | -17.9% |
| IPHI | Buy | INPHI CORP | $9,310,000 | -4.1% | 634,200 | +5.1% | 1.27% | -16.0% |
| CMRX | Buy | CHIMERIX INC | $9,184,000 | -2.4% | 418,600 | +1.6% | 1.25% | -14.5% |
| SDRL | Buy | SEADRILL LIMITED | $9,169,000 | +18.8% | 229,500 | +4.6% | 1.25% | +4.1% |
| NVAX | Buy | NOVAVAX INC | $8,818,000 | +11.8% | 1,908,700 | +9.6% | 1.20% | -2.0% |
| STML | Buy | STEMLINE THERAPEUTICS INC | $8,212,000 | +11.3% | 559,800 | +54.5% | 1.12% | -2.4% |
| BWA | Buy | BORGWARNER INC | $8,188,000 | +18.3% | 125,600 | +11.5% | 1.11% | +3.5% |
| SGMO | Buy | SANGAMO BIOSCIENCES INC | $7,368,000 | -11.9% | 482,500 | +4.3% | 1.00% | -22.8% |
| PWR | Buy | QUANTA SVCS INC | $6,321,000 | +27.8% | 182,800 | +36.4% | 0.86% | +12.0% |
| AGTC | New | APPLIED GENETIC TECHNOL CORP | $4,747,000 | – | 205,500 | +100.0% | 0.65% | – |
| AKBA | New | AKEBIA THERAPEUTICS INC | $4,619,000 | – | 166,200 | +100.0% | 0.63% | – |
| SZYM | Buy | SOLAZYME INC | $4,528,000 | +7.1% | 384,400 | +5.6% | 0.62% | -6.1% |
| CGNX | New | COGNEX CORP | $3,840,000 | – | 100,000 | +100.0% | 0.52% | – |
| MGNX | Buy | MACROGENICS INC | $3,581,000 | +129.0% | 164,800 | +193.2% | 0.49% | +100.4% |
| BLUE | Buy | BLUEBIRD BIO INC | $2,966,000 | +100.7% | 76,900 | +18.3% | 0.40% | +76.0% |
| ATRC | Buy | ATRICURE INC | $2,799,000 | +3.5% | 152,300 | +5.9% | 0.38% | -9.3% |
| SLXP | Buy | SALIX PHARMACEUTICALS INC | $2,689,000 | +26.6% | 21,800 | +6.3% | 0.37% | +10.9% |
| GWPH | New | GW PHARMACEUTICALS PLCads | $2,682,000 | – | 25,000 | +100.0% | 0.36% | – |
| VCYT | New | VERACYTE INC | $2,648,000 | – | 154,700 | +100.0% | 0.36% | – |
| SUPN | Buy | SUPERNUS PHARMACEUTICALS INC | $2,635,000 | +36.7% | 240,600 | +11.6% | 0.36% | +19.7% |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $2,361,000 | – | 52,600 | +100.0% | 0.32% | – |
| RGEN | Buy | REPLIGEN CORP | $2,265,000 | +227.8% | 99,400 | +85.1% | 0.31% | +187.9% |
| XLRN | New | ACCELERON PHARMA INC | $2,110,000 | – | 62,100 | +100.0% | 0.29% | – |
| CBST | Buy | CUBIST PHARMACEUTICALS INC | $2,025,000 | +1.0% | 29,000 | +5.8% | 0.28% | -11.6% |
| CERN | Buy | CERNER CORP | $2,006,000 | -3.1% | 38,900 | +5.7% | 0.27% | -15.0% |
| HPTX | Buy | HYPERION THERAPEUTICS INC | $1,991,000 | +7.6% | 76,300 | +6.4% | 0.27% | -5.6% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $1,879,000 | -2.0% | 30,200 | +7.5% | 0.26% | -14.1% |
| NTUS | Buy | NATUS MEDICAL INC DEL | $1,886,000 | +2.8% | 75,000 | +5.5% | 0.26% | -10.2% |
| INSM | Buy | INSMED INC | $1,770,000 | +29.1% | 88,600 | +23.1% | 0.24% | +13.1% |
| CEMP | Buy | CEMPRA INC | $1,650,000 | -0.2% | 153,800 | +7.4% | 0.22% | -12.8% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $1,438,000 | – | 63,700 | +100.0% | 0.20% | – |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $1,434,000 | +2.0% | 96,600 | +10.7% | 0.20% | -10.6% |
| VSAR | New | VERSARTIS INC | $1,402,000 | – | 50,000 | +100.0% | 0.19% | – |
| ATHN | Buy | ATHENAHEALTH INC | $1,389,000 | -2.6% | 11,100 | +24.7% | 0.19% | -14.5% |
| MEIP | Buy | MEI PHARMA INC | $1,278,000 | -15.6% | 201,600 | +48.1% | 0.17% | -26.0% |
| TGTX | New | TG THERAPEUTICS INC | $1,268,000 | – | 135,000 | +100.0% | 0.17% | – |
| ARWR | New | ARROWHEAD RESH CORP | $1,145,000 | – | 80,000 | +100.0% | 0.16% | – |
| AMBI | Buy | AMBIT BIOSCIENCES CORP | $1,044,000 | -12.7% | 151,100 | +15.3% | 0.14% | -23.7% |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $642,000 | – | 20,000 | +100.0% | 0.09% | – |
| QURE | New | UNIQURE NV | $292,000 | – | 21,466 | +100.0% | 0.04% | – |
| VSTM | New | VERASTEM INC | $189,000 | – | 20,900 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LOWES COS INC | 40 | Q3 2023 | 3.2% |
| PALO ALTO NETWORKS INC | 40 | Q3 2023 | 3.6% |
| ASML HOLDINGS NV | 40 | Q3 2023 | 1.9% |
| NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
| REPLIGEN CORP | 40 | Q3 2023 | 0.5% |
| VERACYTE INC | 38 | Q3 2023 | 1.5% |
| LAM RESEARCH CORP | 35 | Q3 2023 | 3.4% |
| XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.6% |
| MAGNA INTL INC | 33 | Q4 2021 | 2.5% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | February 14, 2023 | 2,589,778 | 3.7% |
| ESSA Pharma Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Freeline Therapeutics Holdings plc | February 14, 2023 | 5,920,765 | 9.1% |
| KnowBe4, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Praxis Precision Medicines, Inc. | February 14, 2023 | 3,518,062 | 7.5% |
| Prometheus Biosciences, Inc. | February 14, 2023 | 1,032,938 | 2.2% |
| SUTRO BIOPHARMA, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Vital Farms, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Zymeworks Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Entasis Therapeutics Holdings Inc. | February 14, 2022 | 590,602 | 1.2% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.